Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

Research output: Contribution to journalArticlepeer-review


  • Cora N Sternberg
  • Daniel P Petrylak
  • Oliver Sartor
  • J Alfred Witjes
  • Tomasz Demkow
  • Jean-Marc Ferrero
  • Jean-Christophe Eymard
  • Silvia Falcon
  • Fabio Calabrò
  • Istvan Bodrogi
  • Peter Harper
  • Manfred Wirth
  • William Berry
  • Michael E Petrone
  • Thomas J McKearn
  • Mojtaba Noursalehi
  • Martine George
  • Marcel Rozencweig

Colleges, School and Institutes


This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.


Original languageEnglish
Pages (from-to)5431-8
Number of pages8
JournalJournal of Clinical Oncology
Issue number32
Publication statusPublished - 2009